Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 13/20 | 0.47 |
| ▸ | ADM2 | Q7Z4H4 | 6/20 | 0.45 |
| ▸ | CALCB | P10092 | 5/20 | 0.44 |
| ▸ | RAMP1 | O60894 | 8/20 | 0.44 |
| ▸ | CALCA | P06881 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978066 | 0.90 | CALCA (0.48) | CALCRLADM2CALCBRAMP1CALCA | |
| SCHEMBL837323 | 0.90 | CALCA (0.48) | CALCRLADM2CALCBRAMP1CALCA | |
| SCHEMBL978829 | 0.90 | CALCA (0.48) | CALCRLADM2CALCBRAMP1CALCA | |
| Trifluoroacetic Acid SCHEMBL837743 | 0.84 | CALCRL (0.51) | CALCRLRAMP1 | |
| SCHEMBL836905 | 0.80 | CALCRL (0.49) | CALCRLADM2CALCBRAMP1CALCA | |
| Hydrochloric Acid SCHEMBL1894269 | 0.79 | CALCRL (0.49) | CALCRLADM2CALCBRAMP1CALCA | |
| SCHEMBL837503 | 0.78 | ADM2 (0.49) | CALCRLADM2CALCBRAMP1CALCA | |
| SCHEMBL1819423 | 0.78 | CALCA (0.52) | CALCRLADM2CALCBRAMP1CALCA | |
| SCHEMBL24962033 | 0.76 | CALCA (0.48) | CALCRLADM2CALCBRAMP1CALCA | |
| SCHEMBL22774650 | 0.76 | CALCA (0.48) | CALCRLADM2CALCBRAMP1CALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765759-B2 | Monocyclic CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2271346-B1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-01-01 | — | — | EP | disclosed |
| EP-2146572-B1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2091533-B1 | CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2012-11-28 | — | — | EP | disclosed |
| US-8173655-B2 | Bicyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8163752-B2 | Tricyclic anilide heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8143266-B2 | Aryl heterocyclic CGRP receptor antagonists | Merck, Sharp & Dohme Corp (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110306626-A1 | IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | Merck, Sharp & Dohme Corp. | 2011-12-15 | — | — | US | disclosed |
| US-7951795-B2 | Constrained spirocyclic compounds as CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP (US) | 2011-01-27 | — | — | US | disclosed |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-03 | — | — | US | disclosed |
| US-20100120809-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-05-13 | — | — | US | disclosed |
| US-20100093759-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-04-15 | — | — | US | disclosed |
| US-20100069359-A1 | CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-03-18 | — | — | US | disclosed |
| EP-2146572-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008130512-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021516-A1 | MONOCYCLIC CGRP RECEPTOR ANTAGONISTS | CCKAR, CALCRL, CCKBR | CALCRL 2/4885ADM2 267/4885CALCB 21/4885 |
| US-20100120809-A1 | ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CCKBR | CALCRL 4/4885ADM2 145/4885CALCB 16/4885 |
| US-20100137328-A1 | TRICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, CCKBR, BDKRB2 | CALCRL 4/4885ADM2 43/4885CALCB 10/4885 |
| US-20110306626-A1 | IMIDAZOLINONE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | CALCRL, BDKRB2, CALCR | CALCRL 1/4885ADM2 156/4885CALCB 18/4885 |
| US-20100093759-A1 | BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CCKBR | CALCRL 5/4885ADM2 48/4885CALCB 14/4885 |
| US-20100069359-A1 | CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS | CALCRL, BDKRB1, CALCR | CALCRL 1/4885ADM2 140/4885CALCB 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.